New stock news | Chuanboat Pharmaceutical is considering listing in Hong Kong and plans to raise approximately $300 million.

According to reports, Bowai Pharmaceuticals is considering listing in Hong Kong and plans to raise approximately $300 million. It is expected to become the largest biopharmaceutical IPO project in Hong Kong since 2024, excluding Jiangsu Hengrui Pharmaceuticals. It is reported that Bowai Pharmaceuticals, as a clinical-stage biotechnology company, is committed to developing a new generation of siRNA drugs to provide better treatment options for global patients. The company has established a rich and differentiated siRNA candidate drug pipeline covering a wide range of indications using its industry-leading RADS (RNA molecules with stronger activity, durability, and safety) platform technology. The company's product pipeline includes cardiovascular diseases, rare diseases, viral infections, metabolic diseases, central nervous system, heart, muscle, fat, and other areas. Among them, cardiovascular drugs BW-01 and BW-02, rare disease drug PKK, and hepatitis B drug HBV have all entered phase II clinical trials. Bowai Pharmaceuticals has gone through several rounds of financing, with investors including Xingze Capital, Zhengxin Valley Capital, CPE Peak Source, Daoyuan Capital, Sanyi Innovation Investment, and Jinshajiang Joint Investment.